Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system (Q41827081)

From Wikidata
Jump to navigation Jump to search
scientific article published on September 1999
edit
Language Label Description Also known as
English
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system
scientific article published on September 1999

    Statements

    Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system (English)

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit